Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2009

01-02-2009 | Breast Oncology

Predicting and Preventing Positive Surgical Margins and Local Failures in Breast-Conserving Surgery

Authors: Dimosthenis Ziogas, MD, Eleftheria Ignatiadou, MD, Michael Fatouros, MD

Published in: Annals of Surgical Oncology | Issue 2/2009

Login to get access

Excerpt

To the Editor …
Literature
1.
Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.PubMedCrossRef
2.
Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol. 2003;10:718–21.PubMedCrossRef
3.
Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther. 2005;5:737–45.PubMedCrossRef
4.
Kurniawan ED, Wong MH, Windle I. Predictors of surgical margin status in breast-conserving surgery within a breast screening program. Ann Surg Oncol. 2008;15:2542–9.PubMedCrossRef
5.
6.
Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.
7.
Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.PubMedCrossRef
8.
Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. 2008;15:21–33.PubMedCrossRef
9.
Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther. 2007;6:308–12.PubMedCrossRef
10.
Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol. 2007;4:578–90.PubMedCrossRef
11.
Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357:1555–6.PubMedCrossRef
12.
Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437–43.PubMedCrossRef
13.
Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol. 2008;26:4360–1.PubMedCrossRef
14.
Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol. 2002;9:607–9.PubMed
15.
Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol. 2002;9:941–3.PubMed
16.
Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol. 2004;11:1030–4.PubMedCrossRef
17.
Chung DC, Yoon SS, Lauwers GY, et al. Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med. 2007;357:283–91.PubMedCrossRef
18.
Ziogas D, Baltogiannis G, Fatouros M, et al. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg. 2008;247:714–5.PubMedCrossRef
19.
Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol. 2002;9:828–30.PubMedCrossRef
20.
Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol. 2004;11:127–9.PubMedCrossRef
21.
Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol. 2007;14:2691–5.PubMedCrossRef
22.
Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol. 2002;9:220–1.PubMedCrossRef
23.
Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther. 2006;6:931–9.PubMedCrossRef
24.
Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery. 1998;123:573–8.PubMedCrossRef
25.
Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn. 2008;8:587–97.PubMedCrossRef
26.
Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn. 2008;8:29–39.PubMedCrossRef
27.
Liakakos T, Roukos DH. More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. 2008;15:956–60.PubMedCrossRef
28.
29.
Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358:197.PubMedCrossRef
30.
Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol. 2008 Aug 23 [Epub ahead of print]. DOI:10.​1245/​s10434-008-0109-6.
Metadata
Title
Predicting and Preventing Positive Surgical Margins and Local Failures in Breast-Conserving Surgery
Authors
Dimosthenis Ziogas, MD
Eleftheria Ignatiadou, MD
Michael Fatouros, MD
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0254-y

Other articles of this Issue 2/2009

Annals of Surgical Oncology 2/2009 Go to the issue

Laboratory and Translational Research

Chemoprotective Effects of Curcuma aromatica on Esophageal Carcinogenesis

Laboratory and Translational Research

Identification of Calreticulin as a Prognosis Marker and Angiogenic Regulator in Human Gastric Cancer

Gastrointestinal Oncology

Cytoreductive Surgery and Continuous Hyperthermic Peritoneal Perfusion in Patients with Mesothelioma and Peritoneal Carcinomatosis: Hemodynamic, Metabolic, and Anesthetic Considerations

Hepatobiliary and Pancreatic Tumors

Induction of Tumor Growth After Preoperative Portal Vein Embolization: Is It a Real Problem?

Hepatobiliary and Pancreatic Tumors

Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population

Gastrointestinal Oncology

Impact of Postoperative Infection on Long-Term Survival After Potentially Curative Resection for Gastric Cancer